Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	Hepatology 2012 (546 pages, free PDF) Hepatitis C 2012 (150 pages, free PDF)	Free Medical Books

Prostate Cancer

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 56 articles: HTML format Text format

Single Articles

April 2012
1. PHILLIP CJ , Giardina CK, Bilir B, Cutler DJ, et al
   Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
   BMC Cancer. 2012;12:145.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   March 2012
2. LASCHAK M , Spindler KD, Schrader AJ, Hessenauer A, et al
   JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.
   BMC Cancer. 2012;12:130.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. THORSEN L , Nilsen TS, Raastad T, Courneya KS, et al
   A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design.
   BMC Cancer. 2012;12:123.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. KONAKA H , Egawa S, Saito S, Yorozu A, et al
   Tri-Modality Therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial.
   BMC Cancer. 2012;12:110.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. LEE CE , Leslie WD, Lau YK
   A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.
   BMC Cancer. 2012;12:103.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. JIA D , Entersz I, Butler C, Foty RA, et al
   Fibronectin matrix-mediated cohesion suppresses invasion of prostate cancer cells.
   BMC Cancer. 2012;12:94.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. PARK JJ , Jin YB, Lee YJ, Lee JS, et al
   KAI1 suppresses HIF-1alpha and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer.
   BMC Cancer. 2012;12:81.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   February 2012
8. MAGBANUA MJ , Sosa EV, Scott JH, Simko J, et al
   Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer.
   BMC Cancer. 2012;12:78.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   January 2012
9. SHAFIQUE K , McLoone P, Qureshi K, Leung H, et al
   Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up.
   BMC Cancer. 2012;12:25.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. FOWKE JH , Motley SS, Concepcion RS, Penson DF, et al
    Obesity, body composition, and prostate cancer.
    BMC Cancer. 2012;12:23.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2011
11. JESPERSEN CG , Noergaard M, Johansen TE, Soegaard M, et al
    The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study.
    BMC Cancer. 2011;11:519.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. GALVAO DA , Taaffe DR, Cormie P, Spry N, et al
    Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial.
    BMC Cancer. 2011;11:517.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. BRAUN M , Menon R, Nikolov P, Kirsten R, et al
    The HOPE fixation technique - a promising alternative to common prostate cancer biobanking approaches.
    BMC Cancer. 2011;11:511.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. BRASE JC , Johannes M, Mannsperger H, Falth M, et al
    TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling.
    BMC Cancer. 2011;11:507.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
15. ELLBERG C , Olsson H
    Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer.
    BMC Cancer. 2011;11:497.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. VALENCIA T , Joseph A, Kachroo N, Darby S, et al
    Role and expression of FRS2 and FRS3 in prostate cancer.
    BMC Cancer. 2011;11:484.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
17. ESKEW JD , Sadikot T, Morales P, Duren A, et al
    Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
    BMC Cancer. 2011;11:468.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. GLYNN RW , Kelly JC, Coffey N, Sweeney KJ, et al
    The effect of breast cancer awareness month on internet search activity - a comparison with awareness campaigns for lung and prostate cancer.
    BMC Cancer. 2011;11:442.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. GRUNDMARK B , Zethelius B, Garmo H, Holmberg L, et al
    Serum levels of selenium and smoking habits at age 50 influence long term prostate cancer risk; a 34 year ULSAM follow-up.
    BMC Cancer. 2011;11:431.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
20. ZHANG H , Xu Y, Zhang Z, Li L, et al
    The hOGG1 Ser326Cys Polymorphism and Prostate Cancer Risk: A Meta-Analysis of 2584 cases and 3234 controls.
    BMC Cancer. 2011;11:391.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
21. WEDEL S , Hudak L, Seibel JM, Makarevic J, et al
    Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
    BMC Cancer. 2011;11:375.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. MANOHAR SM , Padgaonkar AA, Badhwar AJ, Sonawane V, et al
    A novel inhibitor of hypoxia-inducible factor-1alpha P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.
    BMC Cancer. 2011;11:338.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. MATTILA H , Schindler M, Isotalo J, Ikonen T, et al
    NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene.
    BMC Cancer. 2011;11:327.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
24. CHAMBERS SK , Newton RU, Girgis A, Nielsen L, et al
    Living with Prostate Cancer: Randomised Controlled Trial of a Multimodal Supportive Care Intervention for Men with Prostate Cancer.
    BMC Cancer. 2011;11:317.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. PERTEGA-GOMES N , Vizcaino JR, Miranda-Goncalves V, Pinheiro C, et al
    Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer.
    BMC Cancer. 2011;11:312.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
26. LIVINGSTON PM , Salmon J, Courneya KS, Gaskin CJ, et al
    Efficacy of a Referral and Physical Activity Program for Survivors of Prostate Cancer [ENGAGE]: Rationale and Design for a Cluster Randomised Controlled Trial.
    BMC Cancer. 2011;11:237.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. URBANEK C , Goodison S, Chang M, Porvasnik S, et al
    Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer.
    BMC Cancer. 2011;11:233.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. MAHADEVAN NR , Rodvold J, Almanza G, Fernandez Perez A, et al
    ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-kappaB-dependent manner.
    BMC Cancer. 2011;11:229.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. HEINEMANN L , Simpson GR, Boxall A, Kottke T, et al
    Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
    BMC Cancer. 2011;11:221.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
30. HAMMA-KOURBALI Y , Bermek O, Bernard-Pierrot I, Karaky R, et al
    The synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells.
    BMC Cancer. 2011;11:212.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
31. CHIU SC , Wang MJ, Yang HH, Chen SP, et al
    Activation of NAG-1 via JNK signaling revealed an isochaihulactone-triggered cell death in human LNCaP prostate cancer cells.
    BMC Cancer. 2011;11:146.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
32. XU B , Tong N, Chen SQ, Hua LX, et al
    FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls.
    BMC Cancer. 2011;11:84.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. KWAK JT , Hewitt SM, Sinha S, Bhargava R, et al
    Multimodal microscopy for automated histologic analysis of prostate cancer.
    BMC Cancer. 2011;11:62.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. HRBACEK J , Urban M, Hamsikova E, Tachezy R, et al
    Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study.
    BMC Cancer. 2011;11:53.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
35. PERALDO-NEIA C , Migliardi G, Mello-Grand M, Montemurro F, et al
    Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.
    BMC Cancer. 2011;11:31.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. HUGHES KL , Sargeant H, Hawkes AL
    Acceptability of the Distress Thermometer and Problem List to community-based telephone cancer helpline operators, and to cancer patients and carers.
    BMC Cancer. 2011;11:46.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. ECHCHGADDA I , Chang TH, Sabbah A, Bakri I, et al
    Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
    BMC Cancer. 2011;11:43.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. WHEELER DC , Szymanski KM, Black A, Nelson DE, et al
    Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening.
    BMC Cancer. 2011;11:148.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. TAYLOR DJ , Parsons CE, Han H, Jayaraman A, et al
    Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells.
    BMC Cancer. 2011;11:470.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. CRAMB SM , Mengersen KL, Baade PD
    Identification of area-level influences on regions of high cancer incidence in Queensland, Australia: a classification tree approach.
    BMC Cancer. 2011;11:311.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. TOLLE A , Suhail S, Jung M, Jung K, et al
    Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma.
    BMC Cancer. 2011;11:302.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
42. MARESH EL , Mah V, Alavi M, Horvath S, et al
    Differential expression of anterior gradient gene AGR2 in prostate cancer.
    BMC Cancer. 2010;10:680.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. CUPPONE F , Bria E, Giannarelli D, Vaccaro V, et al
    Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials.
    BMC Cancer. 2010;10:675.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. DOZMOROV MG , Azzarello JT, Wren JD, Fung KM, et al
    Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: Implications for prostate cancer progression.
    BMC Cancer. 2010;10:672.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
45. BENCHIKH A , Savage C, Cronin A, Salama G, et al
    A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
    BMC Cancer. 2010;10:635.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. GORLOV IP , Sircar K, Zhao H, Maity SN, et al
    Prioritizing genes associated with prostate cancer development.
    BMC Cancer. 2010;10:599.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
47. MIKI K , Kiba T, Sasaki H, Kido M, et al
    Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial.
    BMC Cancer. 2010;10:572.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. TU WH , Zhu C, Clark C, Christensen JG, et al
    Efficacy of c-Met inhibitor for advanced prostate cancer.
    BMC Cancer. 2010;10:556.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
49. PASTINA I , Giovannetti E, Chioni A, Sissung TM, et al
    Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
    BMC Cancer. 2010;10:511.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. SCHULZ WA , Ingenwerth M, Djuidje CE, Hader C, et al
    Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation.
    BMC Cancer. 2010;10:505.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2010
51. MONSEF N , Soller M, Panagopoulos I, Abrahamsson PA, et al
    HIF1alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiation.
    BMC Cancer. 2010;10:385.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. MARTINEZ-FIERRO ML , Leach RJ, Gomez-Guerra LS, Garza-Guajardo R, et al
    Identification of viral infections in the prostate and evaluation of their association with cancer.
    BMC Cancer. 2010;10:326.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. STRUMPF EC , Chai Z, Kadiyala S
    Adherence to cancer screening guidelines across Canadian provinces: an observational study.
    BMC Cancer. 2010;10:304.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. MULLER I , Wischnewski F, Pantel K, Schwarzenbach H, et al
    Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.
    BMC Cancer. 2010;10:297.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. TUOMELA J , Gronroos TJ, Valta MP, Sandholm J, et al
    Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts.
    BMC Cancer. 2010;10:596.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. TAYLOR W , Mathias A, Ali A, Ke H, et al
    p27(Kip1) deficiency promotes prostate carcinogenesis but does not affect the efficacy of retinoids in suppressing the neoplastic process.
    BMC Cancer. 2010;10:541.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: